Cizzle Biotechnology PLC is a pioneering cancer diagnostics company, originally a spin-out from the University of York, and now listed on the London Stock Exchange.

We have developed a non-invasive blood test for early lung cancer detection, using our patented CIZ1B biomarker technology.

Standing at the forefront of biotechnological innovation, Cizzle’s mission is to improve lung cancer survival through early detection, enabling timely interventions, improving patient outcomes, and saving lives worldwide.